Etienne Sibille

Professor

Centre for Addiction and Mental Health
Country flagCanada
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

The world population is shifting sharply toward an older-age demographic. To navigate the escalating burden of physical and cognitive decline common to aging, and heightened risk of neurodegenerative and neuropsychiatric disease, we require advances in treatment and prevention interventions. These advances are predicated on attaining a deeper understanding of the molecular processes underlying brain aging. Here, we employed novel cis-eQTL and GWAS-based polygenic risk scores (cis-eQTLAGE-PRS and GWASAGE-PRS) indexing genetic risk for accelerated molecular brain aging, and examined their associations with cortical thickness and performance in age-sensitive cognitive domains in 31 384 participants (16 392 women, ages 46-82) from the UK Biobank. While GWASAGE-PRS was nominally associated with lower cortical thickness in frontotemporal regions, cis-eQTLAGE-PRS displayed robust associations with greater cortical thickness in age-sensitive frontal, temporal, and parietal regions, including the left and right precentral (pFDR<0.0001, pFDR=0.05), left insula (pFDR=0.05), as well as the right supramarginal (pFDR=0.05) and precuneus (pFDR=0.05) regions. Similar pFDR trending associations occurred bilaterally in the caudal middle frontal (pFDR=0.052, pFDR=0.078) and right insula (pFDR=0.071). These structural findings co-occurred alongside increased executive function performance on the Trail Making Test B (pFDR=0.035), suggesting a potential neurostructural and cognitive reserve phenotype. This resilience profile may reflect previously uncharacterized pathways of brain reserve in age-related pathology, informing future translational research identifying novel treatment and prevention targets.

Year:

2024

Etienne Sibille, a pioneering figure in neuropsychiatric research, has yet to follow conventional paths. From his early days as a photojournalist editor in New York to becoming one of neuroscience's most innovative voices, his journey reflects the same creative thinking that drives his groundbreaking research at the University of Toronto. As a Professor of Psychiatry, Pharmacology & Toxicology, he brings a fresh perspective to understanding how our brains age and why we get depressed. At the Center for Addiction and Mental Health (CAMH), where he directs the Neurobiology of Depression and Aging research program, his team is turning fascinating discoveries about brain chemistry into potential new treatments. Building on his influential work at Columbia University and the University of Pittsburgh, Sibille has challenged traditional views of brain disorders, particularly through his insights into the GABAergic system and aging. While serving as CAMH's Campbell Chair (2014–2024) and Deputy Director of the Campbell Institute (2017–2020), he has pushed the boundaries between basic research and real-world treatments, recently diving into biopharma development to help bridge this gap. In this Genomic Press Interview, he shares the winding road that led him from behind a camera lens to the forefront of psychiatric research, offering a candid look at what drives his passion for unraveling the brain's mysteries.

Year:

2024

The world population is shifting sharply toward an older-age demographic. To navigate the escalating burden of physical and cognitive decline common to aging, and heightened risk of neurodegenerative and neuropsychiatric disease, we require advances in treatment and prevention interventions. These advances are predicated on attaining a deeper understanding of the molecular processes underlying brain aging. Here, we employed novel GWAS and cis-eQTL-based polygenic risk scores ( GWAS AGE-PRS and cis-eQTL AGE-PRS) indexing genetic risk for accelerated molecular brain aging, and examined their associations with cortical thickness and performance in age-sensitive cognitive domains in 31 384 participants (16 392 women, age 64.1±7.65) from the UK Biobank. While GWAS AGE-PRS was nominally associated with lower cortical thickness in frontotemporal regions, cis-eQTL AGE-PRS displayed robust associations with greater cortical thickness in age-sensitive frontal, temporal, and parietal regions, including the left and right precentral (pFDR<0.0001, pFDR=0.05), left insula (pFDR=0.05), as well as the right supramarginal (pFDR=0.05) and precuneus (pFDR=0.05) regions. Similar pFDR trending associations occurred bilaterally in the caudal middle frontal (pFDR=0.052, pFDR=0.078) and right insula (pFDR=0.071). These structural findings co-occurred alongside increased executive function performance on the Trail Making Test B (pFDR=0.035), suggesting a potential neurostructural and cognitive reserve phenotype. This resilience profile may reflect previously uncharacterized pathways of brain reserve in age-related pathology, informing future translational research identifying novel treatment and prevention targets.

Year:

2024

Cortical GABAergic neuron dysregulation is implicated in schizophrenia (SCZ), but it remains unclear if these changes are due to altered cell proportions or per-cell mRNA changes. We analyzed bulk and cell type-specific RNAseq data from 1,302 individuals to assess SCZ- and age-associated changes in GABAergic interneurons across two neocortical regions. We found that younger SCZ cases (age < 70) showed reduced parvalbumin (PVALB) and somatostatin (SST) cell proportions, while older SCZ cases showed increased proportions compared to controls. Earlier onset SCZ, associated with more severe clinical symptoms, was linked to greater reductions in these cell types. Additionally, there was cohort-specific evidence for reduced per-cell PVALB and SST mRNA in SCZ. Our findings underscore the importance of age-stratified analyses in SCZ, suggesting that distinct pathological processes underlie GABAergic neuron dysregulation across different age- and symptom-severity groups and warranting tailored therapeutic approaches.

Year:

2024

Collaborators (5)

Andreea Diaconescu

Independent Scientist

Centre for Addiction and Mental Health

CANADA
View details

Kevan Clifford

University of Toronto

CANADA
View details

Shreejoy Tripathy

Associate Professor

University of Toronto

CANADA
View details

Thomas D Prevot

Project Scientist

Centre for Addiction and Mental Health

CANADA
View details

Daniel Felsky

Independent Scientist

Centre for Addiction and Mental Health

CANADA
View details